BackBiora Therapeutics Overview

Biora Therapeutics EBIT

Biora Therapeutics's EBIT is $-61M, below the Healthcare sector average of $1.1T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$16.23M
↑ 30.79% YoY

As of Sep 30, 2024

Annual EBIT (TTM)

-$60.98M
↑ 9.94% YoY

Trailing 12 months ending Sep 30, 2024

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Biora Therapeutics (BIORQ) FAQ

The latest EBIT for BIORQ is $-61M as of September 2024. That compares with $-68M in the prior-year period — up 9.9% year over year. That is below the Healthcare sector average of $1.1T. Investors often review this figure alongside Biora Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, BIORQ's EBIT moved from $-68M to $-61M — a 9.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Biora Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, BIORQ currently prints $-61M for EBIT, while the sector average sits near $1.1T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Biora Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-61M for BIORQ is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.1T. Explore the charts below for those layers of context.

After noting BIORQ's EBIT ($-61M), review year-over-year change from $-68M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers